Table 4 Patient demographics and clinical features available for evaluation
| Demographic data | |
| Age | 54 ± 12.5 [24–88], IQR 16.3 |
| Histological data | |
| Receptor status ER (+/−) | negative (22), positive (133), NA (1) |
| Receptor status PR (+/−) | negative (44), positive (110), NA (2) |
| Receptor status HER2 (+/−) | negative (126), positive (16), NA (14) |
| Subtype | basal (12), HER2 (9), luminal (131), NA (4) |
| Molecular subtype | basal (12), HER2 (9), luminalA (113), luminalB (4), NA (18) |
| Grade | 1 (11), 2 (102), 3 (41), NA (2) |
| Lymphovascular space invasion (LVSI) (determined at surgery) | absent (107), present (42), NA (7) |
| Nodal status (determined at surgery) | negative (99), positive (39), micrometastases (11), NA (7) |
|
Disease pathology (multiple conditions allowed per patient) | DCIS (47), IDC (95), ILC (62), LCIS (23) |
| Miscellaneous diagnostic data | |
|
Number of recorded lesions * For some patients, clinical measurements recorded after therapy noted no residual tumour | 0* (7), 1 (133), 2 (14), 3 (2) |
| Laterality | left (87), right (63), bilateral (6) |
| Tumour size | (31 ± 24) [0–128] mm, IQR 26 mm |
| Focality (largest tumour) | unifocal (126), bifocal (12), multifocal (17), NA (1) |
| Type (largest tumour) | ductal (91), lobular (52), both (11), NA (2) |
| Treatment | |
| Surgery | Central excision (1), mastectomy (58), therapeutic mammoplasty (1), WLE (94), NA (2) |
| Neoadjuvant chemoendocrine therapy | no (112), yes (43), NA (1) |
| Survival data | |
| Date of diagnosis | March 2007 – July 2014 |
| Date of imaging | January 2012 – December 2013 |
| Date of surgery | January 2012 – September 2019 |
| Date of death or last follow up | August 2013 – August 2019 |
| Status at last follow-up | alive (140), dead (16) |